An alarming increase in common bacterial infections resistant to antibiotics signals a cause for concern among hospitals worldwide. Experts project that death rates directly linked to drug resistance may soar by the year 2050. As recent as 2023, one in every six laboratory-tested bacterial infections were found to be resistant to antibiotic treatments. The situation aggravates as resistance spreads among predominantly blood, gut, urinary tract, and sexually transmitted infections.
Over the period from 2018 to 2023, more than 40% of commonly used antibiotics have lost their effectiveness against these infections. Countries with lower income and weaker healthcare systems are grappling with this issue the most, reveals the World Health Organization’s Global Antibiotic Resistance Surveillance report. The research collated data, tracing more than 23 million bacterial infections from 104 different countries.
Dr. Yvan Hutin, the director of the WHO’s Department of Antimicrobial Resistance, expresses his concerns: ‘As antibiotic resistance continues to rise, more lives, particularly in countries with weaker healthcare systems and inadequate access to diagnostics and effective medicines, are put at risk.’ There is speculation that the resistance estimates may be skewed for certain territories due to healthcare systems reporting data primarily from specialist hospitals handling severe infections. However, based on the obtained data, WHO estimates that one in three bacterial infections in Southeast Asia and the Eastern Mediterranean, and one in five in Africa, were resistant to antibiotics in 2023.
The targeting of human pathogens by Antimicrobial resistance (AMR) is causing serious concerns. In 2021, drug resistance contributed to 4.71 million of the 7.7 million global deaths from bacterial infections, with 1.14 million directly attributed. Cases of gram-negative bacteria, such as Escherichia coli and Klebsiella pneumoniae, which often cause severe, life-threatening bacterial infections are of major concern.
Dr. Manica Balasegaram from the Global Antibiotic Research and Development Partnership cautions that drug-resistant infections have reached “a critical tipping point”. “To avoid the tipping point, we must now also focus on accelerating innovation and increasing their appropriate use,” he affirms. Prof Sanjib Bhakta, who works to tackle AMR at University College London, highlights the importance of a ‘tailored global action’ to combat AMR. This includes strengthening surveillance and diagnostics, and ensuring equitable access to narrow-spectrum antibiotics. He underlines the importance of preventing infections through cleaner water, better sanitation and hygiene, and vaccination. Reinforced investment in carrying out interdisciplinary, blue-sky research aimed at discovering novel therapeutic interventions against drug-resistant bacteria is urgently needed.